ENTRY       D11404                      Drug
NAME        Asciminib hydrochloride (JAN/USAN);
            Scemblix (TN)
PRODUCT     SCEMBLIX (Novartis Pharmaceuticals Corporation)
FORMULA     C20H18ClF2N5O3. HCl
EXACT_MASS  485.0833
MOL_WEIGHT  486.2994
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG03161  BCR-ABL inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02924  UGT substrate
              DG03190  UGT2B7 substrate
              DG03181  UGT2B17 substrate
REMARK      Therapeutic category: 4291
            ATC code: L01EA06
            Chemical structure group: DG03004
            Product (DG03004): D11404<JP/US>
EFFICACY    Antineoplastic, Tyrosine kinase inhibitor
  DISEASE   Chronic myeloid leukemia (Philadelphia chromosome positive) [DS:H00004]
            Chronic myeloid leukemia (mutation positive) [DS:H00004]
TARGET      BCR-ABL [HSA_VAR:25v1] [HSA:25] [KO:K06619]
  PATHWAY   hsa05200(25)  Pathways in cancer
            hsa05220(25)  Chronic myeloid leukemia
METABOLISM  Enzyme: CYP3A4 [HSA:1576], UGT2B7 [HSA:7364], UGT2B17 [HSA:7367]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EA BCR-ABL tyrosine kinase inhibitors
                 L01EA06 Asciminib
                  D11404  Asciminib hydrochloride (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Asciminib
                D11404  Asciminib hydrochloride (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D11404  Asciminib hydrochloride (JAN/USAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG03161  BCR-ABL inhibitor
                DG03004  Asciminib
                 D11404  Asciminib hydrochloride
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG03004  Asciminib
                 D11404  Asciminib hydrochloride
              DG02924  UGT substrate
               DG03190  UGT2B7 substrate
                DG03004  Asciminib
                 D11404  Asciminib hydrochloride
               DG03181  UGT2B17 substrate
                DG03004  Asciminib
                 D11404  Asciminib hydrochloride
            Drug classes [BR:br08332]
             Antineoplastic
              DG03161  BCR-ABL inhibitor
               D11404  Asciminib hydrochloride
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Non-receptor tyrosine kinases
               ABL family
                BCR-ABL [HSA_VAR:25v1]
                 D11404  Asciminib hydrochloride (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11404
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11404
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11404
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11404
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D11404
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D11404
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG03161  BCR-ABL inhibitor
                DG03004  Asciminib
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG03004  Asciminib
              DG02924  UGT substrate
               DG03190  UGT2B7 substrate
                DG03004  Asciminib
               DG03181  UGT2B17 substrate
                DG03004  Asciminib
DBLINKS     CAS: 2119669-71-3
            PubChem: 384585382
ATOM        32
            1   C8y C    14.9339  -15.4245
            2   C8y C    14.9339  -16.8268
            3   C8x C    16.1257  -17.5279
            4   C8y C    17.3176  -16.8268
            5   C8x C    17.3176  -15.4245
            6   N5x N    16.1257  -14.7234
            7   N1y N    13.6718  -14.7234
            8   C1x C    13.7420  -13.3212
            9   C1x C    12.4098  -12.8304
            10  C1y C    11.5685  -13.9522
            11  C1x C    12.3397  -15.0740
            12  C8y C    13.6718  -17.5279
            13  N5x N    12.3397  -17.1072
            14  N4x N    11.5685  -18.2991
            15  C8x C    12.4098  -19.3508
            16  C8x C    13.7420  -18.9301
            17  O1a O    10.1663  -13.8821
            18  C5a C    18.5797  -17.5279
            19  N1b N    19.7715  -16.8268
            20  O5a O    18.5797  -18.9301
            21  C8y C    20.9634  -17.5279
            22  C8x C    20.9634  -18.9301
            23  C8x C    22.2254  -19.6312
            24  C8y C    23.4173  -18.9301
            25  C8x C    23.4173  -17.5279
            26  C8x C    22.2254  -16.8268
            27  O2a O    24.6793  -19.6312
            28  C1d C    25.8712  -18.9301
            29  X   Cl   27.0631  -19.6312
            30  X   F    26.5724  -17.7382
            31  X   F    25.1701  -17.7382
            32  X   Cl   26.0400  -13.5100
BOND        34
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     1   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11   10  11 1
            12    7  11 1
            13    2  12 1
            14   12  13 2
            15   13  14 1
            16   14  15 1
            17   15  16 2
            18   12  16 1
            19   10  17 1 #Down
            20    4  18 1
            21   18  19 1
            22   18  20 2
            23   19  21 1
            24   21  22 2
            25   22  23 1
            26   23  24 2
            27   24  25 1
            28   25  26 2
            29   21  26 1
            30   24  27 1
            31   27  28 1
            32   28  29 1
            33   28  30 1
            34   28  31 1
///
